skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration


Citeline Awards 2021 - Categories & Entry Criteria

1. Excellence in Innovation in Response to COVID-19 - NEW

2. Champion of Diversity & Inclusion in Clinical Research - NEW

3. Most Successful Early Phase Research (Preclinical & Phase I)

4. Clinical Research Team of the Year

5. Clinical Trial Result of the Year 

6. Excellence in Rare Disease Drug Development

7. Best Patient-facing Technological Initiative

8. Best Sponsor-facing Technology Initiative

9. Clinical Partnership of the Year

10. Best Use of Artificial Intelligence in Clinical Trials

11. Most Innovative Start-up Company

12. Lifetime Achievement 

13. Marquee Award ‘R&D’ Excellence


Excellence in Innovation in Response to COVID-19  - NEW

The pandemic brought on by the coronavirus is the most catastrophic public health crisis of the century.  The arrival of SARS-CoV-2 forced nations across the globe into lockdown, and disrupted personal lives, businesses and organizations in unprecedented ways.  Heeding the call to action, the pharma industry immediately shifted gears and brought a laser focus to the challenge of combating COVID-19.

This Award will recognize the efforts of an individual, team or company for innovative work in developing new treatments, technologies, processes, services or solutions to address the pandemic.  The judges will be looking for novel approaches, resourcefulness, leadership or collaboration that show an effective response to mitigating the impact of the coronavirus pandemic.

To be eligible, activities must have taken place during calendar year 2020.  Entrants must have played a key role in the activity, and all joint parties must be disclosed in the application.

To enter this category, please provide the following:
The name of the individual, team or company, including title/roles
Details of the nominated innovation (e.g., vaccine, drug, diagnostic, technology, service, solution)
If appropriate, include the clinical trial title, phase, sponsor, and trial registration identifier
Describe the innovation, its benefits and impact on combatting the pandemic
If available, please provide documentation in support of the development or achievements described in the entry (a website, URL, press release, etc)

ENTER NOW

 

Champion of Diversity and Inclusion in Clinical Trials - NEW

Enhancing the diversity of clinical trial populations is critical to achieving equity in healthcare and improving health outcomes in our most vulnerable populations.  Historically, clinical trial populations have been rather homogenous, and treatment effect and patient outcomes observed in a trial setting may have limited applicability to the larger ‘real world’ population.  

This Award will recognize a company, team or individual who has demonstrated exceptional initiative in promoting diversity and inclusion of underrepresented populations within a clinical trial or drug development program. The entrant should describe the activities/strategies implemented and the impact they had on patient enrolment. Activities ranging from patient-focused study design, use of technology, awareness and recruitment campaigns, or other creative and innovative approaches will be considered.  Evidence of the impact these activities/strategies had on recruitment should also be included.   

To be eligible, the initiatives undertaken must have been activated during calendar year 2020. 
Entrants must have played a role in the design, launch or execution of the plans, and all joint parties must be disclosed in the application. 

To enter this category, please provide the following:
Full details of the project; i.e. project name (i.e. name of drug candidate or trial title), phase of development, target indication and population studied (if applicable), sponsor(s), and the primary drug(s) tested.
What specific strategies/activities were undertaken? At what point in the study were they deployed?  
Describe the impact the strategies/activities had on study recruitment.  Please share any relevant metrics used for measuring impact.  
If available, please provide documentation (URL) of trial recruitment campaign or any other publicly available sources that illustrate the strategies/activities undertaken.

ENTER NOW

 

Most Successful Early Phase Research (Preclinical & Phase I)

This Award will recognize an early phase research project that met or surpassed its objectives on a range of key performance indicators. The entrant should show that the successful completion of the program was material in enabling the sponsor to advance its drug to the next development phase either on or ahead of schedule and/or keeping within its development budget.

To be eligible, results for the study or program under nomination must have been released during calendar year 2020. 
Entrants must have played a role in the early phase research, and all joint parties must be disclosed in the application. 

To enter this category, please provide the following:


• Full details of the project; i.e. project name (i.e. name of drug candidate or trial title), phase of development, target indication and population studied (if applicable), sponsor(s), and the primary drug(s) tested.

• Summarize the major findings of the study, such as in vitro/in vivo results or primary/co-primary and main secondary endpoints.

• What were the main milestones and deadlines for the preclinical or Phase I study? Please supply evidence of how these were met or surpassed.

• How did this study enable advancement of the drug to the next development stage? 

• If available, please provide documentation (URL) of trial results; i.e. press release, investor presentation, conference abstract/presentation, clinical study report synopsis or other publication.

ENTER NOW

 

Clinical Research Team of the Year


This Award will recognize the clinical research team who have made significant contributions in advancing a new therapy through one or more clinical phases.  The judges will be looking to reward the high performing team that has been most successful in reaching its goals, adopted effective working practices, achieved major milestones within expected timelines, and contributed to the advancement of new therapies.

To be eligible, the core project for the nominated team must be ongoing or completed during calendar year 2020.

Entrants must have played a role in the core project for the product.

To enter this category, please provide the following: 

• The company’s name, the team being entered and basic details of its core project.

• What was the greatest achievement of the team during the qualifying period?
 
• How did all members/functions of the team work together to achieve its goals?

• How does the achievement contribute to advancing new therapies to market?

• What work practices has the team adopted to support the success of the product’s development?

• If you believe that this team is particularly outstanding, but for reasons not covered in the questions above, please give relevant details.

ENTER NOW

 

Clinical Trial Result of the Year 

This Award will recognize the clinical trial which reported results that had the greatest impact and is expected to lead to an advance in healthcare. The judges will be looking to reward the clinical trial with the largest commercial impact, highest impact on patient population, the greatest disruption in a market, or the advancement of clinical trial design. This might include the first demonstration of a clear clinical effect for a new drug in an area of unmet medical need, a pivotal study of a new drug with a breakthrough mechanism of action, or a major study of a potential new or expanded indication for an already marketed product.

To be eligible, results for the study under nomination must have been presented in the public domain during calendar year 2020.

Entrants must have played a role in the clinical study, and all joint parties must be disclosed in the application. 

To enter this category, please provide the following:

• Full details of the study; i.e. trial name (title, protocol ID, trial identifier), phase, disease type and patient segment(s) studied, sponsor(s), and the primary drug(s) tested.

• Summarize the major findings of the study, including all primary/co-primary and main secondary endpoints, and safety endpoints.

• Provide evidence supporting uniqueness and advancement of knowledge in an area of unmet medical need or clinical trial design.

• How do these findings represent a potential leap forward in therapy?

• Documentation (URL) of publicly available trial results required; i.e. press release, conference abstract/presentation, clinical study report synopsis or other publication.

ENTER NOW

 

Excellence in Rare Disease Drug Development

The attempt to combat rare diseases is a challenging task that exemplifies how the pharmaceutical industry addresses unmet medical needs. This Award will recognize the efforts of an individual, team, or company that demonstrated excellence while developing a drug intended to treat rare diseases. The judges will be looking for a drug development program or trial with the largest potential impact in the rare disease space. Outstanding patient centric processes and innovation in study conduct to overcome the various obstacles of rare disease drug development will also be rewarded. 

To be eligible, drug development activities must have taken place during calendar year 2020.  

Entrants must have played a role in drug development and/or trial conduct, and all joint parties must be disclosed in the application. 

To enter this category, please provide the following:

• The name of the individual, team or company, including an outline of their role(s). 

• Details of the drug development program or clinical trial; i.e. rare disease(s) being targeted, name of drug(s), trial name(s) (title, protocol ID, trial identifier), phase, patient segment(s) studied, and sponsor(s).

• Provide evidence of the impact that the drug has had, or potentially could have, on the patient population and addressing unmet medical needs.

• Describe any unique strategies used to ensure successful clinical research conduct within this challenging space, such as trial design, patient centric processes (i.e. close engagement of patient advocacy groups), innovative patient recruitment methods in identifying potential trial participants, or study planning strategies (i.e. use of surrogate markers or original tools and approaches to gather key clinical data).

• If available, please provide documentation (URL) in support of the achievements described.

ENTER NOW

 

Best Patient-facing Technology Initiative

This Award recognizes the promising and disruptive role that digital health technology is currently playing in clinical trials.  Technological innovators are discovering novel ways to gather high quality patient data using an array of digital tools.   Advances in development of smartphone apps, mobile health devices, and a host of other products are revolutionizing the way patients participate in clinical trials. The judges will be looking for the product that represents the best advance in improving patient data collection and/or the patient experience in clinical trials. Those considered may include electronic patient diaries, mobile health devices or any other digital tools that support, encourage or aid the patient’s participation in the clinical trial. 

All recently launched or significantly updated technologies are eligible to enter if they were used in at least one clinical trial during calendar year 2020. 
Companies wishing to enter must have played a role in the development of the nominated technology, and all parties to any joint development agreements should be disclosed in the application.

To enter this category, please provide the following:

• The name of all companies involved in the product development, including an outline of their role(s).

• Specify the date and market of the technology’s first launch, if applicable.

• Outline the key features and benefits of the technology, and how they support the patient’s clinical trial journey.  

• What problems does this product solve and what is novel about it?

• What is the single most significant benefit of the entrant’s technology to users?

• If possible, please provide a link to a product demo (product webpage, YouTube video, etc.).

ENTER NOW

This Award recognizes the vital importance of using the most sophisticated platforms to catalyse and optimize data gathered during clinical trials. Advances in software and applications have a pivotal role to play at all stages of the trial process, assisting Sponsors in effective management of study logistics, monitoring, risk mitigation and timely data collection and analysis.  The judges will be looking for the product or suite of products that help study teams better manage and oversee clinical trial activities.

All recently launched or significantly updated technologies are eligible to enter if they were used in at least one clinical trial during calendar year 2020. 

Companies wishing to enter must have played a role in the development of the nominated technology, and all parties to any joint development agreements should be disclosed in the application.

To enter this category, please provide the following:

• The name of all companies involved in the product development, including an outline of their role(s).

• Specify the date and market of the technology’s first launch, if applicable.

• Outline the key features and benefits of the technology, and how they support the clinical trial process.  Where benefits include cost or time savings, please provide supportive data.

• What problems does this product solve and what is novel about it?

• What is the single most significant benefit of the entrant’s technology to users?

• If possible, please provide a link to a product demo (product webpage, YouTube video, etc.).

ENTER NOW

 

Clinical Partnership of the Year

This Award will be presented to two or more organizations who have set a new benchmark in partnering through collaborative clinical trial activity that took place in 2020.  Partnerships could take place between multiple pharmaceutical and/or biotech companies or between a pharmaceutical and/or biotech company and a contract research organization, research institute, non-profit, or cooperative group. 

To be eligible, the collaborative clinical trial activity in question must be ongoing or completed during calendar year 2020.

Entrants must have played a role in the collaborative clinical trial activity, and all joint parties must be disclosed in the application.

To enter this category, please provide the following:

• Provide the names of organizations involved and basic details of the partnership.

• Why was the partnership novel?

• How does this partnership set a new benchmark for other deals?

• How has partnership achieved an outcome that would not have been possible if partnership had not been created?

• If available, please provide documentation (URL) in support of the achievements described.

ENTER NOW


Best Use of Artificial Intelligence in Clinical Trials

Artificial intelligence (AI) is revolutionizing healthcare and its application in Pharma is gaining momentum.  AI technology provides new opportunities to improve drug discovery, clinical development and commercial adoption of new medicines.  This Award will recognize the efforts of an individual, team, or company in leveraging artificial intelligence to improve a clinical trial process, or to support the successful execution of a clinical trial.  

The judges will be looking for innovative uses of AI that provide a meaningful impact on protocol design, trial execution, or other related activities.  To be eligible, activities must have taken place during calendar year 2020.  Entrants must have played a role in the design, implementation or application of the AI tool, and all joint parties must be disclosed in the application. 

To enter this category, please provide the following:

• The name of the individual, team or company, including an outline of their role(s). 

• Details of the clinical trial or drug development program; i.e. disease(s) being targeted, name of drug(s), trial name(s) (title, protocol ID, trial identifier), phase, patient segment(s) studied, and sponsor(s).

• Describe the utilization of artificial intelligence in the context of the trial/drug development program; if machine learning (ML) is involved, be sure to describe how ML is used.  AI/ML to support any stage of the clinical trial journey may be submitted, including but not limited to:

    o Protocol development, including identification/refinement of study population and entry criteria, study design, endpoint selection
    o Patient recruitment or retention
    o Trial monitoring practices, including safety monitoring
    o Clinical data management

• Evidence of the impact the use of artificial intelligence had (or is having) on the trial/drug development program.  Describe how the use of AI has improved the trial(s) or trial process.  Provide relevant details on how AI has helped reduce costs, improve quality and/or save time.  If available, please provide documentation (URL) in support of the achievements described.

ENTER NOW



Most Innovative Start Up Company

Clinical trials are high risk, expensive, resource-intense undertakings that present significant challenges to small companies with limited financial and human capital.   This award will recognize a start-up biopharmaceutical company that has developed creative and innovative solutions to the formidable challenges that clinical trials present to small organizations.  Solutions may include:  innovative approaches to designing team structures, resourcing solutions, technology, or process/workflow efficiencies around any clinical trial related activity.  Solutions must be those developed or applied during calendar year 2020.

Companies wishing to enter must have designed, delivered and launched the innovation, and all parties to any joint development activities should be disclosed in the application.

To enter this category, please provide the following:

• The name of the company and the innovative solution

• Specify the date of first implementation

• Outline the key features and benefits of the innovation, and the impact it had on the study timeline, costs or quality.  Where applicable, include cost and/or time savings data to support any claims.

• What problems does this innovative approach solve and what is novel about it?

• If possible, please provide additional supporting documentation (process flow chart, Vimeo/YouTube video, etc.).

ENTER NOW

 

Lifetime Achievement
The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their career. This prestigious international Award will go to someone who has had a distinguished career in R&D or clinical research. Nominees may be retired or semi-retired but will still be active in research in some capacity.

For this special Award, candidates must be nominated by a third party.  The nomination should outline in no more than 750 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.

All nominations must include:
• The name of the nominee
• The job title of the nominee (i
f applicable)
• The company name (if applicable)
• Your contact details
• The contact details of the nominee
• A summary of up to 750 words of why you think your nominee is worthy of receiving the Lifetime Achievement Award

ENTER NOW



Marquee Award

This Award honours outstanding achievement, not just in one isolated activity, but across the full spectrum of drug development. The recipient of the marquee award determined by performance metrics derived from Pharma Intelligence's suite of products which indicate commitment, innovation, operational excellence, and success in bringing new medicines to patients. 

 

 




Citeline Awards 2019

The event is a wonderful testimony to the important contributions being made by the industry. Pharma Intelligence, the judges and announcers are all to be congratulated for organizing a stimulating and memorable evening.

Charles DeLisi

The Awards were well presented. The MC did a fabulous job and the winners were allowed to say a few words at the podium.

Makarand Jawadekar

The CARE Awards are a great opportunity to learn about exciting achievements in clinical research, network with the best of the industry and celebrate your own company's achievements by sharing a fun evening of great entertainment, food and drinks.

Farah Ahmad

The CARE Awards Program is a prestigious event acknowledging several different companies for their innovations and accomplishments within the clinical trials ecosystem.  It's a wonderful evening to see/meet the finalists and be part of recognizing the winners.

Joan Chambers

CARE AWARDS are a legitimate awards program that recognizes a wide range of players in the drug/device development sector. Attending the program is definitely worth it.

Joseph Pergolizzi

The evening was a great opportuntiy to take a step back and learn about and celebrate the great work being done in our industry.

Michael Juron

A great place to network and learn about the various services Informa provides!

Raul Soikes

The CARE awards truly represent  the pinnacle in the recognition of excellence in R&D. It is a rare opportunity for the hard working individuals, teams, and organizations to be celebrated for remarkable achievements in the pursuit of the shared objective of improving human health and the quality of life.

Cliff Kalb

Next steps

Citeline Awards 2021

For general inquiries:

Jo Kirkpatrick
Tel: +44 (0) 207 017 7180
Email: jo.kirkpatrick@informa.com

For Sponsorship inquiries:

Christopher Keeling
Tel: +44 (20) 337 73183
Mobile: +44 (0) 7917 647 859
Email: christopher.keeling@informa.com